Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 31.10.2020 at 7:00 AM CET
Settings

Settings

Goto Application

1. WO1996040966 - COMPOSITIONS AND METHODS OF TREATING IL-6 ASSOCIATED DISEASES

Publication Number WO/1996/040966
Publication Date 19.12.1996
International Application No. PCT/US1996/008679
International Filing Date 04.06.1996
IPC
A61K 38/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/47 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C12P 1/00 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
1Preparation of compounds or compositions, not provided for in groups C12P3/-C12P39/121; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
CPC
A61K 38/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
C07K 14/4703
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
4701not used
4702Regulators; Modulating activity
4703Inhibitors; Suppressors
C12P 1/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
1Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
C12R 1/91
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
RPROCESSES USING MICROORGANISMS
1Processes using microorganisms
91using viruses or cell lines
Y02A 50/30
YSECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
50in human health protection, e.g. against extreme weather
30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applicants
  • PRIVATE BIOLOGICALS CORPORATION [US]/[US]
Inventors
  • RODGERS, Thomas, M., Jr.
Agents
  • PABST, Patrea, L.
Priority Data
487,12207.06.1995US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS AND METHODS OF TREATING IL-6 ASSOCIATED DISEASES
(FR) COMPOSITIONS ET PROCEDES DE TRAITEMENT DE MALADIES ASSOCIEES A L'INTERLEUKINE 6 (IL-6)
Abstract
(EN)
Transformed B cell lines secrete into a human serum culture medium under controlled conditions an inhibitor of IL-6. The cell culture medium, or purified fractions thereof having IL-6 inhibitory activity, can be administered to treat patients having disorders characterized by elevated levels of IL-6, particularly certain types of cancers, autoimmune disorders, pain associated with these disorders, side effects arising from chemotherapy, and wasting or other symptoms of certain viral diseases. The preferred cell line is RPMI 1788, from the American Type Culture Collection, although other B cell lines can also be used as a source of active material. Examples demonstrate efficacy in treatment of cancer patients and autoimmune disorders.
(FR)
Des lignées de lymphocytes B transformées sécrètent dans un milieu de culture à base de sérum humain, et dans des conditions régulées, un inhibiteur d'IL-6. Il est possible d'administrer ce milieu de culture cellulaire ou des fractions purifiées de celui-ci, présentant une action inhibitrice par rapport à IL-6, à des patients afin de traiter des affections caractérisées par des niveaux élevés d'IL-6, notamment certains types de cancer, des affections auto-immunes, des douleurs associées à ces troubles, des effets secondaires découlant d'une chimiothérapie, le dépérissement ou d'autres symptômes de certaines maladies d'origine virale. La lignée cellulaire préférée est la lignée RPMI 188, de l'$i(American Type Cell Culture Collection), encore que l'on puisse également faire appel à d'autres lignées de lymphocytes B comme source de substance active. Des exemples démontrent l'efficacité de telles lignées dans le traitement de patients atteints de cancer ainsi que dans le traitement d'affections auto-immunes.
Also published as
Latest bibliographic data on file with the International Bureau